Related Experiment Video
Updated: Feb 9, 2026

Robot-Assisted Kidney Transplantation
Published on: July 19, 2021
Primary Hepatic Burkitt Lymphoma in a Kidney Transplant Recipient
Sophia Lionaki1, Eystratios Tsakonas1, Athina Androulaki2
1Department of Nephrology & Transplantation Unit, Laiko Hospital, National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece.
Abstract:
This is a case of a renal transplant recipient who developed a primary hepatic Burkitt lymphoma a few years after kidney transplantation. The past medical history of the patient was significant for anti-HCV positivity with liver histopathology showing minimal changes of grades 0 and 1, stage 0. She received a graft from a deceased donor, with rabbit antithymocyte globulin and methyl-prednisolone, as induction therapy, and was maintained on azathioprine, cyclosporine, and low dose methyl-prednisolone with normal renal function. Four years after KTx she presented with fatigue, hepatomegaly, and impaired liver function and the workup revealed multiple, variable-sized, low density nodules in the liver, due to diffuse monotonous infiltration of highly malignant non-Hodgkin lymphoma of B-cells, which turned out to be a Burkitt lymphoma. Bone marrow biopsy and spinal fluid exam were free of lymphoma cells. At time of lymphoma diagnosis she was shown to be positive for Epstein-Barr virus polymerase chain reaction. She received aggressive chemotherapy but died due to sepsis, as a result of toxicity of therapy.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Kidney Structure
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...

